Articles: function.
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: The ILLUMINATE study evaluated the superiority of once-daily QVA149 110/50μg, a dual bronchodilator combining the LABA indacaterol and LAMA glycopyrronium, compared to twice-daily LABA/ICS, salmeterol/fluticasone 50/500μg (SFC), in terms of efficacy, safety and tolerability in patients with moderate-to-severe COPD. This analysis reports the efficacy and safety of QVA149 versus SFC in the sub-group population using fixed-dose LABA/ICS prior to study enrollment. ⋯ Karen Mezzi: Employee: Novartis Employee John Pallante: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Acute exacerbations (AEs) have a negative impact on various aspects of the progression of COPD, but objective and detailed data on the impact of hospitalizations for an AE are needed. This study was designed to evaluate the effects of hospitalization on multiple physical parameters in adults with acute exacerbation of COPD. ⋯ The following authors have nothing to disclose: Marie Carmen Valenza, Maria José Flores-Barba, Irene Torres-Sánchez, Gerald Valenza-Demet, Irene Cabrera-Martos, Lydia Martin-MartinNo Product/Research Disclosure Information.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: As the benefits of thrombolytic therapy in patients with pulmonary embolism, with a normal blood pressure and intermediate clinical risk, as determined by right ventricular dysfunction on echocardiography or elevated serum markers of cardiac necrosis, are uncertain, an audit of patients diagnosed with acute PE using MDCTPA was performed to determine the mortality and hemorrhagic complications in-hospital and at 30 days. ⋯ The following authors have nothing to disclose: Carla Nobre, Dinis Mesquita, Boban ThomasNo Product/Research Disclosure Information.
-
Critical Care Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Velocity vector imaging (VVI) has been used to evaluate right ventricular (RV) strain pattern in patients with pulmonary artery hypertension. However, there is limited information on the utility of VVI and modern echocardiographic measurements (e.g. RV/LV end diastolic ratio, Tricuspid annular plane systolic excursion (TASPE), etc.) in predicting ICU and long-term mortality in acute pulmonary embolism (PE). ⋯ The following authors have nothing to disclose: Danai Khemasuwan, Teerapat Yingchoncharoen, Pichapong Tunsupon, Kenya Kusunose, Allan Klein, Ajit Moghekar, Adriano TonelliNo Product/Research Disclosure Information.
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: MonoMAC is a rare syndrome characterized by a haplodeficiency of GATA2 gene products resulting in monocytopenia, B-cell and NK-cell lymphopenia, and an increased susceptibility to atypical infections1 Since its discovery in 2010, there have been only 28 other cases described in the literature. The lack of widespread familiarity with this disease impedes early identification and often leads to mistreatment with near-fatal consequences. Here we describe a case of MonoMAC which eluded diagnosis for over one year. ⋯ As our patient exemplifies, a heightened awareness of this new entity is important to avoid misdiagnosis and inappropriate treatment with chronic steroids given the potential of devastating iatrogenic complications.Reference #1: Vinh et al. Blood 2010;115:1519-1529DISCLOSURE: The following authors have nothing to disclose: Jason Schnack, Aarti Mittal, Ching-Fei ChangNo Product/Research Disclosure Information.